Literature DB >> 1448425

Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.

N Bodor1, T Loftsson, W M Wu.   

Abstract

The soft corticosteroid, loteprednol etabonate (chloromethyl 17 alpha-ethoxycarbonyloxy-11 beta-hydroxy-3-oxoandrosta-1,4-diene-17 beta-carboxylate), I, was designed based on the "inactive metabolite approach." Accordingly, I should be metabolized by hydrolysis to the corresponding inactive cortienic acid derivative, II. The in vitro and in vivo metabolism of I indeed yielded mainly this inactive metabolite, which is more hydrophilic and thus readily eliminated from the body. Relatively high levels of I were found in tissues after intravenous administration of the drug in rats. The permeability of I through hairless mouse skin was comparable to what has been found for related "hard" steroids, without significant metabolism taking place in the skin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1448425     DOI: 10.1023/a:1015849132396

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  6 in total

1.  Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers1?2.

Authors:  N Bodor; Y Oshiro; T Loftsson; M Katovich; W Caldwell
Journal:  Pharm Res       Date:  1984-05       Impact factor: 4.200

2.  Effect of a novel soft steroid on the wound healing of rabbit cornea.

Authors:  N Bodor; M Varga
Journal:  Exp Eye Res       Date:  1990-02       Impact factor: 3.467

3.  Soft drugs. 3. A new class of anticholinergic agents.

Authors:  N Bodor; R Woods; C Raper; P Kearney; J J Kaminski
Journal:  J Med Chem       Date:  1980-05       Impact factor: 7.446

4.  Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials.

Authors:  N Bodor; J J Kaminski; S Selk
Journal:  J Med Chem       Date:  1980-05       Impact factor: 7.446

5.  Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.

Authors:  P Druzgala; G Hochhaus; N Bodor
Journal:  J Steroid Biochem Mol Biol       Date:  1991-02       Impact factor: 4.292

6.  Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.

Authors:  P Druzgala; W M Wu; N Bodor
Journal:  Curr Eye Res       Date:  1991-10       Impact factor: 2.424

  6 in total
  18 in total

1.  Soft drugs based on hydrocortisone: the inactive metabolite approach and its application to steroidal antiinflammatory agents.

Authors:  R J Little; N Bodor; T Loftsson
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

2.  Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.

Authors:  Timothy L Comstock; Michael R Paterno; Kirk M Bateman; Heleen H Decory; Matthew Gearinger
Journal:  Paediatr Drugs       Date:  2012-04-01       Impact factor: 3.022

Review 3.  Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  AAPS J       Date:  2005-12-07       Impact factor: 4.009

Review 4.  Dry eye disease and microbial keratitis: is there a connection?

Authors:  Srihari Narayanan; Rachel L Redfern; William L Miller; Kelly K Nichols; Alison M McDermott
Journal:  Ocul Surf       Date:  2013-01-29       Impact factor: 5.033

Review 5.  Synthesis and pharmacology of anti-inflammatory steroidal antedrugs.

Authors:  M Omar F Khan; Henry J Lee
Journal:  Chem Rev       Date:  2008-12       Impact factor: 60.622

6.  Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats--for safer treatment of gastrointestinal inflammation.

Authors:  N Bodor; T Murakami; W M Wu
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

7.  Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.

Authors:  N Bodor; W M Wu; T Murakami; S Engel
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

8.  Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop.

Authors:  Martin J Coffey; Heleen H Decory; Stephen S Lane
Journal:  Clin Ophthalmol       Date:  2013-02-13

9.  Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery.

Authors:  Timothy L Comstock; Michael R Paterno; Angele Singh; Tara Erb; Elizabeth Davis
Journal:  Clin Ophthalmol       Date:  2011-02-10

10.  Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial.

Authors:  Raymond Fong; Martin Leitritz; Raphaele Siou-Mermet; Tara Erb
Journal:  Clin Ophthalmol       Date:  2012-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.